AU2012217975B2 - Micronized placental tissue compositions and methods for making and using the same - Google Patents

Micronized placental tissue compositions and methods for making and using the same Download PDF

Info

Publication number: AU2012217975B2
Authority: AU; Australia
Prior art keywords: composition; amnion; micronized; chorion; particles
Prior art date: 2011-02-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

AU2012217975A

Other languages

English (en)

Other versions

AU2012217975A1 (en

Inventor

John Daniel

Brenda S. Morse

Steven Ray

Somaly SITH

Randall Spencer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Mimedx Group Inc

Original Assignee

Mimedx Group Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-02-14

Filing date

2012-02-13

Publication date

2015-11-19

2012-02-13 Application filed by Mimedx Group Inc filed Critical Mimedx Group Inc

2013-09-26 Publication of AU2012217975A1 publication Critical patent/AU2012217975A1/en

2015-11-19 Application granted granted Critical

2015-11-19 Publication of AU2012217975B2 publication Critical patent/AU2012217975B2/en

2016-02-16 Priority to AU2016200972A priority Critical patent/AU2016200972B2/en

2017-09-14 Priority to AU2017228658A priority patent/AU2017228658B2/en

2019-11-29 Priority to AU2019272042A priority patent/AU2019272042B2/en

2022-01-31 Priority to AU2022200614A priority patent/AU2022200614B2/en

Status Active legal-status Critical Current

2032-02-13 Anticipated expiration legal-status Critical

Links

239000000203 mixture Substances 0.000 title claims abstract description 188
210000005059 placental tissue Anatomy 0.000 title claims description 19
238000000034 method Methods 0.000 title abstract description 55
210000001691 amnion Anatomy 0.000 claims description 126
210000001519 tissue Anatomy 0.000 claims description 117
239000002245 particle Substances 0.000 claims description 83
210000001136 chorion Anatomy 0.000 claims description 73
210000003491 skin Anatomy 0.000 claims description 33
230000029663 wound healing Effects 0.000 claims description 20
239000000463 material Substances 0.000 claims description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
239000012867 bioactive agent Substances 0.000 claims description 10
210000004207 dermis Anatomy 0.000 claims description 10
230000002500 effect on skin Effects 0.000 claims description 10
210000002919 epithelial cell Anatomy 0.000 claims description 10
210000002950 fibroblast Anatomy 0.000 claims description 10
239000000243 solution Substances 0.000 claims description 9
230000036573 scar formation Effects 0.000 claims description 8
206010061218 Inflammation Diseases 0.000 claims description 7
230000004054 inflammatory process Effects 0.000 claims description 7
239000007788 liquid Substances 0.000 claims description 7
229920001577 copolymer Polymers 0.000 claims description 6
239000000499 gel Substances 0.000 claims description 6
238000002347 injection Methods 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
239000011780 sodium chloride Substances 0.000 claims description 6
230000037303 wrinkles Effects 0.000 claims description 5
239000000872 buffer Substances 0.000 claims description 4
230000001413 cellular effect Effects 0.000 claims description 4
230000002708 enhancing effect Effects 0.000 claims description 4
239000008363 phosphate buffer Substances 0.000 claims description 4
229920000642 polymer Polymers 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
102000012422 Collagen Type I Human genes 0.000 claims description 3
108010022452 Collagen Type I Proteins 0.000 claims description 3
108010080379 Fibrin Tissue Adhesive Proteins 0.000 claims description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
229940030225 antihemorrhagics Drugs 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000002874 hemostatic agent Substances 0.000 claims description 3
229920002674 hyaluronan Polymers 0.000 claims description 3
229960003160 hyaluronic acid Drugs 0.000 claims description 3
239000012981 Hank's balanced salt solution Substances 0.000 claims description 2
229920001340 Microbial cellulose Polymers 0.000 claims description 2
239000007983 Tris buffer Substances 0.000 claims description 2
239000007853 buffer solution Substances 0.000 claims description 2
210000001612 chondrocyte Anatomy 0.000 claims description 2
210000005081 epithelial layer Anatomy 0.000 claims description 2
210000003195 fascia Anatomy 0.000 claims description 2
239000007972 injectable composition Substances 0.000 claims description 2
230000000968 intestinal effect Effects 0.000 claims description 2
235000015110 jellies Nutrition 0.000 claims description 2
239000008274 jelly Substances 0.000 claims description 2
239000011159 matrix material Substances 0.000 claims description 2
239000002687 nonaqueous vehicle Substances 0.000 claims description 2
210000003516 pericardium Anatomy 0.000 claims description 2
229920001059 synthetic polymer Polymers 0.000 claims description 2
210000004876 tela submucosa Anatomy 0.000 claims description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
206010063395 Dural tear Diseases 0.000 claims 1
230000001737 promoting effect Effects 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract description 9
230000003169 placental effect Effects 0.000 abstract description 9
239000010410 layer Substances 0.000 description 89
-1 for example Chemical compound 0.000 description 41
208000027418 Wounds and injury Diseases 0.000 description 38
206010052428 Wound Diseases 0.000 description 35
230000008439 repair process Effects 0.000 description 25
238000001356 surgical procedure Methods 0.000 description 23
235000014113 dietary fatty acids Nutrition 0.000 description 22
229930195729 fatty acid Natural products 0.000 description 22
239000000194 fatty acid Substances 0.000 description 22
238000001035 drying Methods 0.000 description 20
238000012545 processing Methods 0.000 description 18
210000000988 bone and bone Anatomy 0.000 description 16
150000004665 fatty acids Chemical class 0.000 description 16
230000000699 topical effect Effects 0.000 description 15
239000003431 cross linking reagent Substances 0.000 description 14
150000001875 compounds Chemical class 0.000 description 13
210000002826 placenta Anatomy 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
208000014674 injury Diseases 0.000 description 12
238000011282 treatment Methods 0.000 description 12
125000004432 carbon atom Chemical group C* 0.000 description 11
210000004027 cell Anatomy 0.000 description 11
238000006297 dehydration reaction Methods 0.000 description 11
230000035876 healing Effects 0.000 description 11
210000005036 nerve Anatomy 0.000 description 11
231100000241 scar Toxicity 0.000 description 11
230000004888 barrier function Effects 0.000 description 10
210000000981 epithelium Anatomy 0.000 description 10
150000002191 fatty alcohols Chemical class 0.000 description 10
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 10
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
230000018044 dehydration Effects 0.000 description 9
230000008569 process Effects 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
210000004872 soft tissue Anatomy 0.000 description 9
230000004927 fusion Effects 0.000 description 8
210000004379 membrane Anatomy 0.000 description 8
239000012528 membrane Substances 0.000 description 8
229920001983 poloxamer Polymers 0.000 description 8
229920001223 polyethylene glycol Polymers 0.000 description 8
238000012360 testing method Methods 0.000 description 8
230000008733 trauma Effects 0.000 description 8
241001269524 Dura Species 0.000 description 7
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 7
229920002274 Nalgene Polymers 0.000 description 7
239000002202 Polyethylene glycol Substances 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000006378 damage Effects 0.000 description 7
230000007547 defect Effects 0.000 description 7
210000002615 epidermis Anatomy 0.000 description 7
GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 7
102000008186 Collagen Human genes 0.000 description 6
108010035532 Collagen Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 6
239000003242 anti bacterial agent Substances 0.000 description 6
229940088710 antibiotic agent Drugs 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000011248 coating agent Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
229920001436 collagen Polymers 0.000 description 6
239000003995 emulsifying agent Substances 0.000 description 6
150000002170 ethers Chemical class 0.000 description 6
239000000945 filler Substances 0.000 description 6
REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 6
238000012216 screening Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 6
239000011800 void material Substances 0.000 description 6
229920000690 Tyvek Polymers 0.000 description 5
239000012984 antibiotic solution Substances 0.000 description 5
210000002469 basement membrane Anatomy 0.000 description 5
229960000541 cetyl alcohol Drugs 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 5
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
238000011049 filling Methods 0.000 description 5
239000012530 fluid Substances 0.000 description 5
238000000227 grinding Methods 0.000 description 5
239000006210 lotion Substances 0.000 description 5
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 5
229920000151 polyglycol Polymers 0.000 description 5
239000010695 polyglycol Substances 0.000 description 5
238000000926 separation method Methods 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
KJIOQYGWTQBHNH-UHFFFAOYSA-N undecanol Chemical compound CCCCCCCCCCCO KJIOQYGWTQBHNH-UHFFFAOYSA-N 0.000 description 5
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
210000001789 adipocyte Anatomy 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000003416 augmentation Effects 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
239000006071 cream Substances 0.000 description 4
230000007423 decrease Effects 0.000 description 4
239000003599 detergent Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
239000003102 growth factor Substances 0.000 description 4
FIPPFBHCBUDBRR-UHFFFAOYSA-N henicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCO FIPPFBHCBUDBRR-UHFFFAOYSA-N 0.000 description 4
IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 4
BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 4
239000007943 implant Substances 0.000 description 4
XGFDHKJUZCCPKQ-UHFFFAOYSA-N nonadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCO XGFDHKJUZCCPKQ-UHFFFAOYSA-N 0.000 description 4
CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
230000000399 orthopedic effect Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000003495 polar organic solvent Substances 0.000 description 4
229960000502 poloxamer Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002265 prevention Effects 0.000 description 4
230000008929 regeneration Effects 0.000 description 4
238000011069 regeneration method Methods 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 description 4
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 4
229960002666 1-octacosanol Drugs 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
239000004971 Cross linker Substances 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
102000016942 Elastin Human genes 0.000 description 3
108010014258 Elastin Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
108010073385 Fibrin Proteins 0.000 description 3
102000009123 Fibrin Human genes 0.000 description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
241000711549 Hepacivirus C Species 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
102000016611 Proteoglycans Human genes 0.000 description 3
108010067787 Proteoglycans Proteins 0.000 description 3
208000002847 Surgical Wound Diseases 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
238000013019 agitation Methods 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
210000004381 amniotic fluid Anatomy 0.000 description 3
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
239000000356 contaminant Substances 0.000 description 3
238000005202 decontamination Methods 0.000 description 3
230000003588 decontaminative effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
229920002549 elastin Polymers 0.000 description 3
210000003414 extremity Anatomy 0.000 description 3
230000035558 fertility Effects 0.000 description 3
239000000835 fiber Substances 0.000 description 3
229950003499 fibrin Drugs 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
238000003306 harvesting Methods 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
235000021317 phosphate Nutrition 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
229920001451 polypropylene glycol Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
210000004994 reproductive system Anatomy 0.000 description 3
230000037390 scarring Effects 0.000 description 3
239000002904 solvent Substances 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
230000001954 sterilising effect Effects 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
150000003467 sulfuric acid derivatives Chemical class 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000017423 tissue regeneration Effects 0.000 description 3
210000003454 tympanic membrane Anatomy 0.000 description 3
230000002792 vascular Effects 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical compound CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241001260012 Bursa Species 0.000 description 2
208000032544 Cicatrix Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
201000009273 Endometriosis Diseases 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
206010019909 Hernia Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000025157 Oral disease Diseases 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
229920002582 Polyethylene Glycol 600 Polymers 0.000 description 2
ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
241000209140 Triticum Species 0.000 description 2
235000021307 Triticum Nutrition 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000002280 amphoteric surfactant Substances 0.000 description 2
230000003872 anastomosis Effects 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
239000000560 biocompatible material Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000010478 bone regeneration Effects 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
208000028831 congenital heart disease Diseases 0.000 description 2
238000001816 cooling Methods 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
239000004053 dental implant Substances 0.000 description 2
238000002845 discoloration Methods 0.000 description 2
229960000735 docosanol Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 2
238000009472 formulation Methods 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
201000005562 gingival recession Diseases 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
238000002684 laminectomy Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
229920002113 octoxynol Polymers 0.000 description 2
208000025661 ovarian cyst Diseases 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000006072 paste Substances 0.000 description 2
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
210000002379 periodontal ligament Anatomy 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
230000010399 physical interaction Effects 0.000 description 2
229920000223 polyglycerol Polymers 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
239000002243 precursor Substances 0.000 description 2
238000004321 preservation Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
230000037387 scars Effects 0.000 description 2
239000000565 sealant Substances 0.000 description 2
239000000344 soap Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
230000008961 swelling Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
239000003634 thrombocyte concentrate Substances 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
210000001177 vas deferen Anatomy 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
239000001993 wax Substances 0.000 description 2
239000002888 zwitterionic surfactant Substances 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
CFOQKXQWGLAKSK-KTKRTIGZSA-N (13Z)-docosen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCO CFOQKXQWGLAKSK-KTKRTIGZSA-N 0.000 description 1
RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
BZANQLIRVMZFOS-ZKZCYXTQSA-N (3r,4s,5s,6r)-2-butoxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound CCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BZANQLIRVMZFOS-ZKZCYXTQSA-N 0.000 description 1
HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
JXNPEDYJTDQORS-HZJYTTRNSA-N (9Z,12Z)-octadecadien-1-ol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCO JXNPEDYJTDQORS-HZJYTTRNSA-N 0.000 description 1
IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 description 1
JXNPEDYJTDQORS-AVQMFFATSA-N (9e,12e)-octadeca-9,12-dien-1-ol Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCO JXNPEDYJTDQORS-AVQMFFATSA-N 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
239000005968 1-Decanol Substances 0.000 description 1
XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
229940094997 1-tetracosanol Drugs 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
GOHZKUSWWGUUNR-UHFFFAOYSA-N 2-(4,5-dihydroimidazol-1-yl)ethanol Chemical class OCCN1CCN=C1 GOHZKUSWWGUUNR-UHFFFAOYSA-N 0.000 description 1
CBYYPIYKJZCKGK-UHFFFAOYSA-N 2-(4-azidophenyl)-2-oxoacetaldehyde;hydrate Chemical compound O.[N-]=[N+]=NC1=CC=C(C(=O)C=O)C=C1 CBYYPIYKJZCKGK-UHFFFAOYSA-N 0.000 description 1
RRBZUCWNYQUCTR-UHFFFAOYSA-N 2-(aminoazaniumyl)acetate Chemical class NNCC(O)=O RRBZUCWNYQUCTR-UHFFFAOYSA-N 0.000 description 1
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
BCFOOQRXUXKJCL-UHFFFAOYSA-N 4-amino-4-oxo-2-sulfobutanoic acid Chemical class NC(=O)CC(C(O)=O)S(O)(=O)=O BCFOOQRXUXKJCL-UHFFFAOYSA-N 0.000 description 1
QQZOUYFHWKTGEY-UHFFFAOYSA-N 4-azido-n-[2-[2-[(4-azido-2-hydroxybenzoyl)amino]ethyldisulfanyl]ethyl]-2-hydroxybenzamide Chemical compound OC1=CC(N=[N+]=[N-])=CC=C1C(=O)NCCSSCCNC(=O)C1=CC=C(N=[N+]=[N-])C=C1O QQZOUYFHWKTGEY-UHFFFAOYSA-N 0.000 description 1
YRLKXQVDEQEYSN-UHFFFAOYSA-N 4-azidobenzohydrazide Chemical compound NNC(=O)C1=CC=C(N=[N+]=[N-])C=C1 YRLKXQVDEQEYSN-UHFFFAOYSA-N 0.000 description 1
DKGXIVRSAKPDHF-UHFFFAOYSA-N 6-chloro-3-methyl-1-phenylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(=O)C=C(Cl)N1C1=CC=CC=C1 DKGXIVRSAKPDHF-UHFFFAOYSA-N 0.000 description 1
IKYKEVDKGZYRMQ-IUQGRGSQSA-N 9,12,15-Octadecatrien-1-ol Chemical compound CC\C=C\C\C=C\C\C=C\CCCCCCCCO IKYKEVDKGZYRMQ-IUQGRGSQSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical class CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
108010001478 Bacitracin Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010008164 Cerebrospinal fluid leakage Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
229910000531 Co alloy Inorganic materials 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000001187 Collagen Type III Human genes 0.000 description 1
108010069502 Collagen Type III Proteins 0.000 description 1
208000002330 Congenital Heart Defects Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
208000014997 Crohn colitis Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229920001651 Cyanoacrylate Polymers 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 description 1
WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
206010061619 Deformity Diseases 0.000 description 1
229920004943 Delrin® Polymers 0.000 description 1
208000008960 Diabetic foot Diseases 0.000 description 1
206010056340 Diabetic ulcer Diseases 0.000 description 1
ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
208000003790 Foot Ulcer Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
208000005230 Leg Ulcer Diseases 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000422980 Marietta Species 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
208000008883 Patent Foramen Ovale Diseases 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
208000006389 Peri-Implantitis Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000004210 Pressure Ulcer Diseases 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
108010009736 Protein Hydrolysates Proteins 0.000 description 1
108010081750 Reticulin Proteins 0.000 description 1
208000026137 Soft tissue injury Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
208000020339 Spinal injury Diseases 0.000 description 1
206010072005 Spinal pain Diseases 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
208000002240 Tennis Elbow Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
229910001069 Ti alloy Inorganic materials 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 description 1
206010045210 Tympanic Membrane Perforation Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046798 Uterine leiomyoma Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
229910001080 W alloy Inorganic materials 0.000 description 1
NKRHXEKCTWWDLS-UHFFFAOYSA-N [W].[Cr].[Co] Chemical compound [W].[Cr].[Co] NKRHXEKCTWWDLS-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
239000011354 acetal resin Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
229920003232 aliphatic polyester Polymers 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
210000001909 alveolar process Anatomy 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000001166 anti-perspirative effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003213 antiperspirant Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229960003071 bacitracin Drugs 0.000 description 1
229930184125 bacitracin Natural products 0.000 description 1
CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
239000003855 balanced salt solution Substances 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
VYLDEYYOISNGST-UHFFFAOYSA-N bissulfosuccinimidyl suberate Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)C(S(O)(=O)=O)CC1=O VYLDEYYOISNGST-UHFFFAOYSA-N 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
238000007675 cardiac surgery Methods 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000005754 cellular signaling Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940081733 cetearyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
238000009390 chemical decontamination Methods 0.000 description 1
SZMZREIADCOWQA-UHFFFAOYSA-N chromium cobalt nickel Chemical compound [Cr].[Co].[Ni] SZMZREIADCOWQA-UHFFFAOYSA-N 0.000 description 1
ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
230000035602 clotting Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000002826 coolant Substances 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
150000001896 cresols Chemical class 0.000 description 1
239000013078 crystal Substances 0.000 description 1
NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000023753 dehiscence Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
210000004268 dentin Anatomy 0.000 description 1
239000002781 deodorant agent Substances 0.000 description 1
230000036576 dermal application Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000003618 dip coating Methods 0.000 description 1
ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
210000000613 ear canal Anatomy 0.000 description 1
210000000959 ear middle Anatomy 0.000 description 1
210000001513 elbow Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000009836 endodontic lesion Effects 0.000 description 1
229920006351 engineering plastic Polymers 0.000 description 1
230000009986 erectile function Effects 0.000 description 1
230000003628 erosive effect Effects 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
229920002313 fluoropolymer Polymers 0.000 description 1
239000004811 fluoropolymer Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
230000007027 foramen ovale closure Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002682 general surgery Methods 0.000 description 1
DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
210000004195 gingiva Anatomy 0.000 description 1
208000007565 gingivitis Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229930182478 glucoside Natural products 0.000 description 1
239000003292 glue Substances 0.000 description 1
MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000003752 hydrotrope Substances 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000000819 hypertonic solution Substances 0.000 description 1
229940021223 hypertonic solution Drugs 0.000 description 1
125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000000077 insect repellent Substances 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000009413 insulation Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000001788 irregular Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
210000000281 joint capsule Anatomy 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
229940048848 lauryl glucoside Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
201000010260 leiomyoma Diseases 0.000 description 1
JXNPEDYJTDQORS-UHFFFAOYSA-N linoleyl alcohol Natural products CCCCCC=CCC=CCCCCCCCCO JXNPEDYJTDQORS-UHFFFAOYSA-N 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000007769 metal material Substances 0.000 description 1
HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002324 minimally invasive surgery Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
230000003020 moisturizing effect Effects 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
229910001000 nickel titanium Inorganic materials 0.000 description 1
HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
GIMSVYFIIWHJBJ-UHFFFAOYSA-N octadec-9-ene-1,1-diol Chemical compound CCCCCCCCC=CCCCCCCCC(O)O GIMSVYFIIWHJBJ-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
ALSTYHKOOCGGFT-MDZDMXLPSA-N oleyl alcohol Chemical compound CCCCCCCC\C=C\CCCCCCCCO ALSTYHKOOCGGFT-MDZDMXLPSA-N 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
238000012856 packing Methods 0.000 description 1
LBIYNOAMNIKVKF-FPLPWBNLSA-N palmitoleyl alcohol Chemical compound CCCCCC\C=C/CCCCCCCCO LBIYNOAMNIKVKF-FPLPWBNLSA-N 0.000 description 1
LBIYNOAMNIKVKF-UHFFFAOYSA-N palmitoleyl alcohol Natural products CCCCCCC=CCCCCCCCCO LBIYNOAMNIKVKF-UHFFFAOYSA-N 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
239000011236 particulate material Substances 0.000 description 1
210000004417 patella Anatomy 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000003239 periodontal effect Effects 0.000 description 1
201000001245 periodontitis Diseases 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920000139 polyethylene terephthalate Polymers 0.000 description 1
239000005020 polyethylene terephthalate Substances 0.000 description 1
229920001522 polyglycol ester Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000011471 prostatectomy Methods 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000007665 sagging Methods 0.000 description 1
206010039722 scoliosis Diseases 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000009589 serological test Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
208000011818 severe chest pain Diseases 0.000 description 1
210000002832 shoulder Anatomy 0.000 description 1
239000002356 single layer Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000004528 spin coating Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
150000003871 sulfonates Chemical class 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229910052715 tantalum Inorganic materials 0.000 description 1
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
MINQXXMPECOAGH-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO MINQXXMPECOAGH-UHFFFAOYSA-N 0.000 description 1
230000008719 thickening Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
238000007483 tonsillectomy Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940100617 topical lotion Drugs 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
229920000428 triblock copolymer Polymers 0.000 description 1
YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
238000009810 tubal ligation Methods 0.000 description 1
RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
210000001644 umbilical artery Anatomy 0.000 description 1
210000003954 umbilical cord Anatomy 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
229940057402 undecyl alcohol Drugs 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
239000012808 vapor phase Substances 0.000 description 1
238000007631 vascular surgery Methods 0.000 description 1
238000007879 vasectomy Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
230000037373 wrinkle formation Effects 0.000 description 1
210000000707 wrist Anatomy 0.000 description 1
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Cell Biology (AREA)
Developmental Biology & Embryology (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Immunology (AREA)
Virology (AREA)
Zoology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU2012217975A 2011-02-14 2012-02-13 Micronized placental tissue compositions and methods for making and using the same Active AU2012217975B2 (en)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
AU2016200972A AU2016200972B2 (en)	2011-02-14	2016-02-16	Micronized placental tissue compositions and methods for making and using the same
AU2017228658A AU2017228658B2 (en)	2011-02-14	2017-09-14	Micronized placental tissue compositions and methods for making and using the same
AU2019272042A AU2019272042B2 (en)	2011-02-14	2019-11-29	Micronized placental tissue compositions and methods of making and using the same
AU2022200614A AU2022200614B2 (en)	2011-02-14	2022-01-31	Micronized placental tissue compositions and methods of making and using the same

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201161442348P	2011-02-14	2011-02-14
US61/442,348		2011-02-14
US201161543995P	2011-10-06	2011-10-06
US61/543,995		2011-10-06
PCT/US2012/024798 WO2012112410A2 (fr)	2011-02-14	2012-02-13	Compositions micronisées de tissu placentaire, et méthodes de fabrication et d'utilisation de celles-ci

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2016200972A Division AU2016200972B2 (en)	2011-02-14	2016-02-16	Micronized placental tissue compositions and methods for making and using the same

Publications (2)

Publication Number	Publication Date
AU2012217975A1 AU2012217975A1 (en)	2013-09-26
AU2012217975B2 true AU2012217975B2 (en)	2015-11-19

Family

ID=46673099

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
AU2012217975A Active AU2012217975B2 (en)	2011-02-14	2012-02-13	Micronized placental tissue compositions and methods for making and using the same
AU2016200972A Active AU2016200972B2 (en)	2011-02-14	2016-02-16	Micronized placental tissue compositions and methods for making and using the same
AU2017228658A Active AU2017228658B2 (en)	2011-02-14	2017-09-14	Micronized placental tissue compositions and methods for making and using the same
AU2019272042A Active AU2019272042B2 (en)	2011-02-14	2019-11-29	Micronized placental tissue compositions and methods of making and using the same
AU2022200614A Active AU2022200614B2 (en)	2011-02-14	2022-01-31	Micronized placental tissue compositions and methods of making and using the same

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
AU2016200972A Active AU2016200972B2 (en)	2011-02-14	2016-02-16	Micronized placental tissue compositions and methods for making and using the same
AU2017228658A Active AU2017228658B2 (en)	2011-02-14	2017-09-14	Micronized placental tissue compositions and methods for making and using the same
AU2019272042A Active AU2019272042B2 (en)	2011-02-14	2019-11-29	Micronized placental tissue compositions and methods of making and using the same
AU2022200614A Active AU2022200614B2 (en)	2011-02-14	2022-01-31	Micronized placental tissue compositions and methods of making and using the same

Country Status (2)

Country	Link
AU (5)	AU2012217975B2 (fr)
WO (1)	WO2012112410A2 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5906252B2 (ja) *	2010-12-20	2016-04-20	ステムニオン，インコーポレイテッド	歯科疾患、障害、および損傷の治療方法
AU2012217982B2 (en)	2011-02-14	2016-05-12	Mimedx Group Inc.	Tissue grafts modified with a cross-linking agent and method of making and using the same
KR102903446B1 (ko)	2011-02-14	2025-12-24	미메딕스 그룹 인크.	마이크로화된 태반 조직 조성물 및 이의 제조 및 사용 방법
US12290613B2 (en) *	2011-10-06	2025-05-06	Mimedx Group, Inc.	Micronized compositions composed of bone grafts and methods of making and using the same
WO2013082412A1 (fr)	2011-12-02	2013-06-06	Mimedx Group, Inc.	Greffons de tissu placentaire produits par déshydratation chimique/ séchage par congélation et procédés de production et d'utilisation correspondants
US9162011B2 (en)	2011-12-19	2015-10-20	Allosource	Flowable matrix compositions and methods
CA2857636C (fr)	2011-12-22	2020-06-23	Mimedx Group Inc.	Greffes de tissu placentaire deshydratees reticulees et procedes pour fabriquer et utiliser celles-ci
US11338063B2 (en)	2012-08-15	2022-05-24	Mimedx Group, Inc.	Placental tissue grafts modified with a cross-linking agent and methods of making and using the same
US9943551B2 (en) *	2012-08-15	2018-04-17	Mimedx Group, Inc.	Tissue grafts composed of micronized placental tissue and methods of making and using the same
US8904664B2 (en)	2012-08-15	2014-12-09	Mimedx Group, Inc.	Dehydration device and methods for drying biological materials
EP2884944B1 (fr)	2012-08-15	2020-10-07	MiMedx Group, Inc.	Greffes de tissu placentaire renforcées et procédés de fabrication et d'utilisation de celles-ci
US9180145B2 (en)	2012-10-12	2015-11-10	Mimedx Group, Inc.	Compositions and methods for recruiting and localizing stem cells
US8946163B2 (en)	2012-11-19	2015-02-03	Mimedx Group, Inc.	Cross-linked collagen comprising metallic anticancer agents
US9155799B2 (en)	2012-11-19	2015-10-13	Mimedx Group, Inc.	Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent
HK1218373A1 (zh) *	2012-12-27	2017-02-17	Lotus Tissue Repair Inc.	用於治療年齡相關失調的重組膠原蛋白7的給予
US10517931B2 (en)	2013-01-17	2019-12-31	Mimedx Group, Inc.	Non-surgical, localized delivery of compositions for placental growth factors
US9827293B2 (en)	2013-01-17	2017-11-28	Mimedx Group, Inc.	Non-surgical, localized delivery of compositions for placental growth factors
US9655948B1 (en)	2013-01-17	2017-05-23	Mimedx Group, Inc.	Non-surgical, localized delivery of compositions for placental growth factors
US10206977B1 (en)	2013-01-18	2019-02-19	Mimedx Group, Inc.	Isolated placental stem cell recruiting factors
JP6545102B2 (ja) *	2013-01-18	2019-07-17	ミメディクスグループインコーポレイテッド	心病態を治療する方法
CA2899246C (fr)	2013-03-13	2022-12-06	Allosource	Compositions fibreuses de fascia et leurs procedes d'utilisation et de fabrication
WO2014149953A1 (fr) *	2013-03-15	2014-09-25	Cryolife, Inc.	Procédés de préparation d'implants de tissu
US10029030B2 (en) *	2013-03-15	2018-07-24	Mimedx Group, Inc.	Molded placental tissue compositions and methods of making and using the same
WO2014150784A1 (fr)	2013-03-15	2014-09-25	Allosource	Matrice de collagène repeuplée de cellules pour réparation et régénération des tissus mous
US10039792B1 (en) *	2013-03-16	2018-08-07	Brahm Holdings, Llc	Methods for the treatment of inflammation and pain using human birth tissue material composition
EP3038630B1 (fr)	2013-08-30	2020-03-18	MIMEDX Group Inc.	Compositions placentaires micronisées comprenant un chélateur
EP3043771A4 (fr) *	2013-09-10	2017-05-03	MIMEDX Group Inc.	Utilisations cosmétiques de compositions placentaires moulées
KR102161901B1 (ko)	2013-12-06	2020-10-05	알로소스	조직의 시트를 건조하는 방법
WO2015109329A1 (fr)	2014-01-17	2015-07-23	Mimedx Group, Inc.	Méthode pour induire l'angiogenèse
WO2015175776A1 (fr) *	2014-05-14	2015-11-19	NuTech Medical, Inc.	Préparations de membrane placentaire, et leurs procédés de fabrication et d'utilisation pour régénérer un cartilage et des disques intervertébraux de la colonne vertébrale
US20150335686A1 (en) *	2014-05-21	2015-11-26	Mimedx Group, Inc.	Micronized wharton's jelly
TW201603818A (zh) *	2014-06-03	2016-02-01	組織科技股份有限公司	組成物及方法
US20160008410A1 (en)	2014-07-08	2016-01-14	Mimedx Group, Inc.	Micronized wharton's jelly
AU2015308795B2 (en)	2014-08-28	2019-05-23	Mimedx Group, Inc.	Collagen reinforced tissue grafts
AU2015315228B2 (en) *	2014-09-09	2019-03-21	Mimedx Group, Inc.	Micronized placental tissue compositions with optional sealant and methods of making and using the same
KR102683921B1 (ko)	2014-10-28	2024-07-11	바이오보텍 에이에스	미분화된 알껍데기 막 입자, 및 상처 치유를 촉진시키기 위한 이것의 용도
US10342830B2 (en)	2015-01-05	2019-07-09	Gary M. Petrucci	Methods and materials for treating lung disorders
US10736990B2 (en)	2015-02-11	2020-08-11	Mimedx Group, Inc.	Collagen and micronized placental tissue compositions and methods of making and using the same
KR101701227B1 (ko) *	2015-02-12	2017-02-13	고려대학교 산학협력단	양막 및 융모막의 복합추출물을 유효성분으로 함유하는 골형성 촉진용 약학적 조성물
WO2016207355A1 (fr)	2015-06-24	2016-12-29	Biovotec As	Échafaudages produits par ingénierie tissulaire comprenant de la membrane de coquille d'œuf sous forme particulaire
CN105018417B (zh) *	2015-07-22	2018-11-23	中国人民解放军第二军医大学	负载羊膜固有干细胞的冻存活性羊膜微粒及其条件培养基与应用
EP3349812B1 (fr) *	2015-09-17	2021-01-06	Stimlabs LLC	Compositions dérivées de placenta et procédés pour les produire
EP3349813B1 (fr) *	2015-09-17	2021-09-01	Stimlabs LLC	Compositions dérivées de placenta et procédés pour les produire
GB201519923D0 (en)	2015-11-11	2015-12-23	Biovotec Dac And Biovotec As	Dry biocompatible disintegrateable films for delivering particulate egg shell membrane to a wound
US10993969B2 (en)	2016-02-05	2021-05-04	Gary M. Petrucci	Methods and materials for treating nerve injuries and neurological disorders
AU2017316682B2 (en)	2016-08-24	2020-10-15	Arthrex, Inc.	Tissue use for repair of injury
KR101824521B1 (ko) *	2016-12-26	2018-02-01	고려대학교 산학협력단	양막 및 융모막의 복합추출물을 유효성분으로 함유하는 골형성 촉진용 약학적 조성물
US10772986B2 (en)	2017-01-26	2020-09-15	Allosource	Fascia fibrous compositions and methods for their use and manufacture
CN107349463A (zh) *	2017-06-16	2017-11-17	卓阮医疗科技（苏州）有限公司	一种生物源性止血微粒及其制备方法
US10478531B2 (en) *	2017-06-22	2019-11-19	Gary M. Petrucci	Methods and materials for treating blood vessels
US10251917B1 (en)	2017-09-19	2019-04-09	Gary M. Petrucci	Methods and materials for treating tumors
US11154641B2 (en)	2017-12-22	2021-10-26	Stimlabs Llc	Translucent, dehydrated placental tissue and methods of producing and using the same
US11511017B2 (en)	2019-03-12	2022-11-29	Arthrex, Inc.	Ligament reconstruction
AU2021324670A1 (en) *	2020-08-11	2023-02-02	Musculoskeletal Transplant Foundation	Method for treating cardiac conditions with placenta-derived compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040048796A1 (en) *	2002-03-26	2004-03-11	Hariri Robert J.	Collagen biofabric and methods of preparation and use therefor
WO2004026244A2 (fr) *	2002-09-18	2004-04-01	Emiliano Ghinelli	Utilisation d'une composition a base de membrane amniotique humaine dans la prophylaxie et le traitement de maladies et d'etats pathologiques de l'oeil et de la peau
US20070021762A1 (en) *	2005-07-13	2007-01-25	Qing Liu	Ocular plug formed from placenta derived collagen biofabric

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0431164A4 (en) *	1989-04-21	1992-06-03	Kishinevsky Selskokhozyaistvenny Institut Imeni M.V. Frunze	Preparation with an anti-inflammatory, lactogenous and stimulating action, and method of obtaining it
US20070299043A1 (en) *	2005-10-03	2007-12-27	Hunter William L	Anti-scarring drug combinations and use thereof
WO2008021391A1 (fr) *	2006-08-15	2008-02-21	Anthrogenesis Corporation	Biomatériau à base de cordon ombilical pour usage médical
CA2736663C (fr) *	2007-09-07	2018-01-02	Surgical Biologics, Llc.	Greffons de tissu placentaire et procedes ameliores pour leur preparation et leur utilisation
GB0816496D0 (en) *	2008-09-10	2008-10-15	Zhao Xiaobin	Hyaluronic acid cryogel
WO2012003377A2 (fr) *	2010-06-30	2012-01-05	Tissuetech, Inc.	Procédé de préparation de tissu chorial et produits dérivés dudit tissu

2012
- 2012-02-13 AU AU2012217975A patent/AU2012217975B2/en active Active
- 2012-02-13 WO PCT/US2012/024798 patent/WO2012112410A2/fr not_active Ceased
2016
- 2016-02-16 AU AU2016200972A patent/AU2016200972B2/en active Active
2017
- 2017-09-14 AU AU2017228658A patent/AU2017228658B2/en active Active
2019
- 2019-11-29 AU AU2019272042A patent/AU2019272042B2/en active Active
2022
- 2022-01-31 AU AU2022200614A patent/AU2022200614B2/en active Active

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040048796A1 (en) *	2002-03-26	2004-03-11	Hariri Robert J.	Collagen biofabric and methods of preparation and use therefor
WO2004026244A2 (fr) *	2002-09-18	2004-04-01	Emiliano Ghinelli	Utilisation d'une composition a base de membrane amniotique humaine dans la prophylaxie et le traitement de maladies et d'etats pathologiques de l'oeil et de la peau
US20070021762A1 (en) *	2005-07-13	2007-01-25	Qing Liu	Ocular plug formed from placenta derived collagen biofabric

Also Published As

Publication number	Publication date
AU2019272042B2 (en)	2021-11-04
AU2017228658A1 (en)	2017-10-05
AU2019272042A1 (en)	2019-12-19
AU2022200614B2 (en)	2025-01-30
WO2012112410A2 (fr)	2012-08-23
WO2012112410A3 (fr)	2013-01-24
AU2016200972A1 (en)	2016-03-03
AU2016200972B2 (en)	2017-06-15
AU2022200614A1 (en)	2022-02-24
AU2017228658B2 (en)	2019-08-29
AU2012217975A1 (en)	2013-09-26

Publication	Publication Date	Title
US11931384B2 (en)	2024-03-19	Micronized placental tissue compositions and methods of making and using the same
AU2022200614B2 (en)	2025-01-30	Micronized placental tissue compositions and methods of making and using the same
US20180221418A1 (en)	2018-08-09	Micronized placental tissue compositions and methods of making and using the same
US12070528B2 (en)	2024-08-27	Collagen and micronized placental tissue compositions and methods of making and using the same

Legal Events

Date	Code	Title	Description
2016-03-17	FGA	Letters patent sealed or granted (standard patent)